OxiGene completes enrollment in trial evaluating CA4P with chemotherapy

By Elaine Rigoli

Tampa, Fla., March 23 - OxiGene Inc. has completed patient enrollment in a phase 2 clinical trial for the treatment of imageable solid tumors, which will evaluate the safety and anticancer activity of the triple combination of Combretastatin A4P (CA4P) together with widely used chemotherapy agents carboplatin and paclitaxel.

The objectives of the randomized, open-label trial are to assess the safety of several doses of CA4P in combination with the two chemotherapeutic agents, gather data on antitumor activity and establish a recommended phase 2/3 dose, according to a company news release.

The study will assess, by magnetic resonance imaging, changes in tumor blood flow, which may provide additional insight into the biological activity of CA4P, the release said.

OxiGene is a Waltham, Mass.-based pharmaceutical company developing novel small-molecule therapeutics to treat cancer and eye diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.